Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL™ PF for the Treatment of Presbyopia

LONDON--(BUSINESS WIRE)--Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, today reported positive topline results from BRIO-II, the company’s second Phase 3 pivotal trial. BRIO-II met the pre-specified primary endpoints agreed upon with the U.S. FDA, and European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA), demonstrating statistically significant imp